Home
Adaptive Designs in Clinical Drug Development
3 February - 4 February 2010
Adaptive Designs in Clinical Drug Development

 Adaptive Design

After the success of last year's conference, SAE Media Group is proud to present their 4th Annual Adaptive Designs in Clinical Drug Development.

This conference is aimed at exploring the potential of adaptive trials now and in the future through looking at the process, from design through to implementation.  The process will be emphasised and explained at all times by reference to real case studies.

You will hear presentations from the key players in the adaptive arena on the big questions adaptive design.  Is an adaptive design suitable for my needs?  What is the regulatory position on adaptive design?  How do I build in adaption to my design?  Will a seamless design prove any benefit?  How do you manage the additional challenges of data collection, storage and manipulation?  Where is the future for adaptive designs?

Attend this event to learn what adaptive designs can add to your clinical drug development experience.

Fancy speaking at the conference?  Do you know of anyone who may be interested in speaking?  We are always on the look-out for new speakers for our upcoming conferences.  Let us know: SAE Media Groupproduction@SAE Media Group-online.co.uk.

For sponsorship and exhibitioning opportunities, contact sponsorshipdept@SAE Media Group-online.co.uk

 Adaptive Design

 

Alun Bedding
Director, Biostatistics and Programming Development Partners, Drug Development Sciences
GlaxoSmithKline

Carl-Fredrik Burman
Senior Principal Scientist
AstraZeneca

Graeme Archer
Director, Neurosciences Discovery Biometrics
GlaxoSmithKline

Robert Clay
Vice President Regulatory Affairs, Oncology and Infection
AstraZeneca

Edwin Wagena
Vice President Clinical Development
Kiadis Pharma

Junfang Li
Director, Biostatistics & Programming Department
Sanofi-Aventis

 

Conference agenda

clock

8:30

Registration & Coffee

clock

8:30

Registration and coffee

clock

9:00

Welcome & Introductions

clock

9:00

Welcome and introductions

clock

9:10

Background to Adaptive Designs

  • The Combination Testing principle
  • Adaptive seamless designs
  • The Closed Testing principle
  • clock

    9:10

    Overview

  • What are the key stages in the adaptive clinical trial design process?
  • Setting the scene for the hands-on exercises which follow
  • clock

    9:50

    Statistical Issues

  • Testing procedures for multi-armed designs
  • Designing parameters
  • Comparison of the procedures
  • Overall p-values and confidence intervals
  • clock

    9:50

    Evaluating

  • A number of trial design options will be presented
  • Delegates will evaluate each design option
  • clock

    10:30

    Morning Tea

    clock

    10:30

    Morning tea

    clock

    10:50

    Practical Performance

  • Software for planning and analysing multi-armed trials
  • Practical examples
  • clock

    10:50

    Comparing and optimising adaptive clinical trials

  • How can adaptive designs be optimised
  • Delegates will get the opportunity to compare and optimise a variety of design options
  • clock

    11:30

    Discussion session

    clock

    12:00

    Close of Workshop

    clock

    12:00

    Close of workshop

    clock

    13:30

    Registration and coffee

    clock

    14:00

    Welcome and introductions

    clock

    14:10

    Planning: how do you know you have a good design?

    clock

    15:10

    Afternoon tea

    clock

    15:30

    Implementation: are you fully prepared to implement adaptive changes?

    clock

    16:30

    Discussion session

    clock

    17:00

    Close of workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Robert Clay

    Robert Clay, Vice President Regulatory Affairs, Oncology and Infection, AstraZeneca

    clock

    9:05

    ADAPTIVE DESIGN REGULATION IN THE EU AND JAPAN

    Robert Clay

    Robert Clay, Vice President Regulatory Affairs, Oncology and Infection, AstraZeneca

  • Adaptive trials in the EU
  • Adaptive trials in Japan
  • Creating a global outlook with a high level of standardisation
  • clock

    9:40

    LARGE RANDOMISED PIVOTAL TRIAL IN CANCER

    Lothar Tremmel

    Lothar Tremmel, Senior Director and Group Leader, Biostatistics, Cephalon

  • An adaptive group sequential design used in a large, randomised trial used for a successful NDA in cancer
  • Regulatory interactions, concerns and how they were addressed
  • How the adaptive group sequential design fares as compared to traditional group sequential design
  • clock

    10:15

    LATE STAGE AND SEAMLESS ADAPTIVE TRIAL CASE STUDIES

    Yannis Jemiai

    Yannis Jemiai, Associate Director of Biostatistics, Cytel

  • Phase III oncology trial - applying adaptive sample size re-assessment in a survival set-up
  • Phase III cardiovascular trial - the critical advantage of adaptive population enrichment
  • Phase II/III seamless adaptive trial - understanding methodology, rules, regulatory view and logistics
  • clock

    10:50

    Morning Coffee

    clock

    11:20

    ADAPTIVE TRIALS AND TRADITIONAL DESIGNS

    Christopher Jennison

    Christopher Jennison, Professor of Statistics and Dean of the Faculty of Science, University of Bath

  • Choosing between fixed sample, group sequential and adaptive designs
  • Waiting to specify the power curve: an adaptation too far
  • Seamless Phase II/Phase III: simplicity vs. efficiency
  • Multiple treatments, multiple populations: when only "adaptation" works
  • The bigger picture: looking beyond a single stage of the drug development process
  • clock

    11:55

    OPTIMAL GROUP SEQUENTIAL DESIGNS

    Fredrik Ohrn

    Fredrik Ohrn, Senior Statistician, AstraZeneca

  • Briefly show how designs with optimal efficiency can be derived
  • Make efficiency comparisons with an existing method from the literature
  • Compare adaptive and non-adaptive designs
  • Give examples of easily implementable error spending versions of non-adaptive designs
  • clock

    12:30

    DOSE SELECTION IN EARLY PHASE CLINICAL TRIALS

    Barbara Bogacka

    Barbara Bogacka, Reader in Probability and Statistics, Queen Mary, University of London

  • Different adaptive designs including PK/PD data
  • Using PK/PD data effectively when considering dose selection
  • Optimising selection with respect to the chosen criterion for the trial
  • clock

    13:05

    Networking Lunch

    clock

    14:05

    REAL-TIME COLLECTION IN ADAPTIVE TRIALS TODAY

  • Examining real-time data capture in adaptive trials: overcoming the challenges and creating the most efficient strategy possible
  • Real time simulations, analysis and decision-making: establishing new solutions
  • The effective, immediate implementation of these solutions
  • Alan Eggleston

    Alan Eggleston, Global Head of Sales and Marketing, Cmed Group Ltd

    Martin Kimber

    Martin Kimber, Clinical Trials Consultant, Tessella Support Services Plc

    clock

    14:40

    ADAPTIVE TRIAL DESIGNS FOR ONCOLOGY TRIALS

    Tom Parke

    Tom Parke, Head of Clinical Technologies, Tessella Support Services Plc

  • Benefits for oncology of adaptive trials
  • Difficulties presented by progression free survival endpoint
  • Several real examples
  • clock

    15:15

    Afternoon Tea

    clock

    15:45

    SPECIAL ADDRESS: THE ROLE OF SIMULATION

    Graeme Archer

    Graeme Archer, Senior Director, Neurosciences Discovery Biometrics, GlaxoSmithKline

  • Adaptive designs can be highly efficient mechanisms to investigate NCEs in early POC studies
  • They also lend themselves to a more relevant form of statistical interference: Bayesian reasoning
  • Simulation methods can be used to understand the operating characteristics of any design
  • This talk will demonstrate how such methods have been used in a variety of neuroscience POC studies in GSK
  • clock

    16:20

    A SHORTCUT TO PERSONALISED MEDICINE?

    Yu Shyr

    Yu Shyr, Professor & Chief, Division of Cancer Biostatistics, Vanderbilt University

  • Biomarkers vs. surrogate endpoints
  • Prognostic biomarker vs. perdictive biomarker
  • Biomarker-adaptive threshold design
  • Adaptive signature design
  • High-dimensional biomarker trail design
  • clock

    16:55

    THE CASINO APPROACH TO MULTIPLICITY

    Carl-Fredrik Burman

    Carl-Fredrik Burman, Statistical Science Director, AstraZeneca

  • Do you want to draw several confirmatory conclusions from you trial?
  • Then FDA requires tight control of the overall (type I) error rate alpha
  • Learn how to safeguard alpha with a brand new method
  • Draw simple graphs and forget about the maths!
  • See the implications on adaptive designs with dose selection
  • Apply your knowledge in our Virtual Casino and win amazing prizes...
  • clock

    17:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Alun Bedding

    Alun Bedding, Director, Biostatistics and Programming Development Partners, Drug Development Sciences, GlaxoSmithkline

    clock

    9:10

    KEYNOTE PRESENTATION: A BAYESIAN ADAPTIVE RANDOMISATION DESIGN IN RESPIRATORY MEDICINE

    Alun Bedding

    Alun Bedding, Director, Biostatistics and Programming Development Partners, Drug Development Sciences, GlaxoSmithkline

  • Setting the scene for using adaptive randomisation
  • Details of the endpoints and modelling
  • Simulation of the design and impact on the size and duration of the study
  • Some logistic hurdles

     

  • clock

    9:50

    TREATMENT SELECTION BY DESIGN

    Sue Todd

    Sue Todd, Reader in Medical Statistics, University of Reading

  • An adaptive design for treatment selection and evaluation
  • Exploration in the context of a study in Multiple Sclerosis
  • Simulation study of the properties of alternative designs
  • clock

    10:30

    BAYESIAN ADAPTIVE RANDOMISATION FOR A PHASE II ONCOLOGY TRIAL

    Pantelis Vlachos

    Pantelis Vlachos, Principal Biostatistician, Merck Serono

  • Classical vs adaptive randomisation 
  • Simulation of course of trial
  • Evaluation of trial operating characteristics
  • Logistic and practical issues
  • clock

    11:10

    Morning Coffee

    clock

    11:40

    A RECENT CASE STUDY OF OPERATIONAL SEAMLESS PHASE II/III DESIGN

    Loïc Darchy

    Loïc Darchy, Senior Statistician, Sanofi-Aventis R&D

  • Trial design - main challenges
  • Feedback from health authorities
  • Overall Type I error control
  • Comparison to another design
  • Discussion - lessons learnt
  • clock

    12:20

    A BAYESIAN ADAPTIVE RANDOMISATION IIA/IIB STUDY

    Yili Pritchett

    Yili Pritchett, Research Fellow, Director Clinical Statistics, Abbott Laboratories

  • Going through the mathematical components of the design
  • Illustration of the dynamic updates as real data accumulate
  • Calculation of the savings made using the adaptive design
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    SEAMLESS PHASE II/III ADAPTIVE DESIGN WITH DOSE SELECTION

    Caroline Morgan

    Caroline Morgan, Director of Clinical Operations, Cardinal Systems (CRO)

  • Superiority and non-inferiority comparisons
  • Pre-study simulations
  • Parallel scientific advice (FDA & EMEA) and PDCO
  • Optimising the clinical trial workflow
  • clock

    14:40

    IMPLEMENTING ADAPTIVE DESIGN: A TECHNOLOGY PERSPECTIVE

    Scott Hamilton

    Scott Hamilton, Senior Director, Biometrics and Randomisation Technologies, United BioSource Corporation

  • Clinical technologies and clinical trials
  • Adaptive design implementation challenges
  • Strategies for a successful implementation
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    PHASE II/III ADPTIVE DESIGN WITH TREATMENT SELECTION

    David Lawrence

    David Lawrence, Senior Statistician, Novartis

  • Trial design of a confirmatory study with pre-planned adaption at interim
  • Interim decision making
  • The role of the sponsor
  • Recommendations for ASDs in this setting
  • clock

    16:30

    THE CLASSIC BAUER-KOHNE ADAPTIVE DESIGN

    Vera Lisovskaja

    Vera Lisovskaja, Researcher, Biostatistics, AstraZeneca

  • A very popular type of adaptive design could lead to illogical conclusions
  • A drug can be "proved" to be efficacious, although the average effect is no better than a placebo
  • Learn a simple way to protect your analysis from such anomolies
  • Choose sample size re-estimations, for which the improved test is as powerful as the original
  • clock

    17:10

    Chairman’s Closing Remarks and Close of Day Two

    Workshops

    Adaptive Designs for Multi-Armed Trials

    Adaptive Designs for Multi-Armed Trials

    Crowne Plaza Hotel - St James
    2 February 2010
    London, United Kingdom

    Planning for Success: Adapt by Design

    Planning for Success: Adapt by Design

    Crowne Plaza Hotel - St James
    2 February 2010
    London, United Kingdom

    A Practical Lesson in Adaptive Trial Design

    A Practical Lesson in Adaptive Trial Design

    Crowne Plaza Hotel - St James
    5 February 2010
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.